[시장보고서]족저근막염 치료 시장 규모, 점유율 및 동향 분석 보고서 : 약물 클래스별, 질환 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

족저근막염 치료 시장 규모, 점유율 및 동향 분석 보고서 : 약물 클래스별, 질환 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Plantar Fasciitis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids), By Disease Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869882

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,858,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,347,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,324,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

족저근막염 치료 시장 요약

세계의 족저근막염 치료 시장 규모는 2024년에 12억 8,000만 달러로 평가되었고, 2033년까지 34억 5,000만 달러에 이를 것으로 예측됩니다.

2025-2033년의 CAGR은 11.9%를 나타낼 전망입니다. 시장 성장의 주요 촉진요인으로는 비만 유병률 증가, 인구 고령화, 장시간 서 있거나 고강도 활동으로 인한 발뒤꿈치 및 발 부상 사례 증가에 의해 주도되고 있습니다.

환자들의 발 건강에 대한 인식 제고, 전문 치료 접근성 향상, 첨단 치료 옵션 도입이 시장 확장을 더욱 뒷받침하고 있습니다. 병원, 클리닉, 외래 진료 시설은 발 관련 질환의 조기 진단과 효과적인 관리를 강조하고 있습니다. 이러한 요소들이 결합되어 치료적 개입에 대한 수요를 촉진하며, 발뒤꿈치 및 발 관리 부문에서 꾸준한 성장과 혁신을 이끌고 있습니다.

정부가 정확한 글로벌 사례 수치를 제공하는 경우는 드물지만, 추정치에 따르면 매년 약 100만 건의 환자 방문이 족저근막염으로 인한 것으로 나타납니다. 연구에 따르면 인구의 약 10%가 일생 중 어느 시점에 족저근막염을 경험하며, 이 중 83%는 25세에서 65세 사이의 활동적인 직장인입니다. 일부 연구에서는 러너들 사이에서 유병률이 22%에 달한다고 보고합니다.

영상 유도 시술, 초음파 유도 주사, 최소 침습적 기계적 또는 음향 치료의 발전은 표적 정확도를 높이고 회복 시간을 단축하며 효과를 향상시켜 의료진과 환자의 수용도를 높이고 있습니다. 2025년 7월, 미국 물리 의학 재활 학회지에 게재된 연구는 족저근막염 치료에서 혈소판 풍부 혈장(PRP)과 코르티코스테로이드의 효능을 비교했습니다. 결과에 따르면 PRP는 코르티코스테로이드 주사보다 우수한 통증 완화 효과와 발 기능 개선 효과를 보였습니다. 또한 2025년 7월, 러크나우 소재 킹 조지 의과대학 연구진이 만성 발뒤꿈치 통증 치료를 위한 초음파 유도 포도당 증식 요법과 PRP 주사의 효과를 비교한 연구를 발표했습니다. 연구 결과 두 치료법 모두 통증을 현저히 감소시키고 발 기능을 개선했으며, PRP가 약간 더 우수한 결과를 보였습니다.

지역별 시장 점유율 분석(2024년 및 2033년)
지역별 시장 대시보드
시장 규모와 예측 동향 분석(2021-2033년)
북미
- 국가별(2021-2033년)
- 미국
- 캐나다
- 멕시코
유럽
- 국가별(2021-2033년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 국가별(2021-2033년)
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 국가별(2021-2033년)
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별(2021-2033년)
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일
- Pfizer Inc.
- Bayer AG
- Johnson &Johnson
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- AbbVie Inc.
- GSK plc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.

HBR

영문 목차

영문목차

Plantar Fasciitis Treatment Market Summary

The global plantar fasciitis treatment market size was estimated at USD 1.28 billion in 2024 and is projected to reach USD 3.45 billion by 2033, growing at a CAGR of 11.9% from 2025 to 2033. The market growth is driven by rising prevalence of obesity, an aging population, and an increase in heel and foot strain cases caused by prolonged standing or high-impact activities.

Increasing awareness among patients about foot health, better access to specialized care, and the adoption of advanced treatment options are further supporting market expansion. Hospitals, clinics, and outpatient facilities are emphasizing early diagnosis and effective management of foot-related conditions. Combined, these factors are fueling demand for therapeutic interventions, driving consistent growth and encouraging innovation within the heel and foot care segment.

Although governments rarely provide exact global case figures, estimates suggest that approximately 1 million patient visits yearly are due to plantar fasciitis. Research indicates that around 10% of the population experience plantar fasciitis at some point, with 83% of affected individuals being active working adults aged 25 to 65. Some studies report prevalence rates as high as 22% among runners.

Developments in image-guided interventions, ultrasound-guided injections, and minimally invasive mechanical or sonic therapies improve targeting, reduce recovery time, and enhance efficacy, thus increasing physician and patient adoption. In July 2025, a study published in the American Journal of Physical Medicine & Rehabilitation compared the efficacy of platelet-rich plasma (PRP) and corticosteroids in treating plantar fasciitis. The results indicated that PRP provided superior pain relief and improved foot function over corticosteroid injections. In addition, in July 2025, a study by King George's Medical University researchers in Lucknow explored the effectiveness of ultrasound-guided dextrose prolotherapy versus PRP injections for chronic heel pain. The study found that both treatments significantly reduced pain and improved foot function, with PRP demonstrating slightly superior outcomes.

Global Plantar Fasciitis Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global plantar fasciitis treatment market report based on drug class, disease type, end use, and region:

Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Others
Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)
Acute Plantar Fasciitis
Chronic Plantar Fasciitis
Others
End Use Outlook (Revenue, USD Billion, 2021 - 2033)
Hospitals & Clinics
Ambulatory Surgical Centers
Others
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Disease Type
- 1.2.3. End Use
- 1.2.4. Region
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Plantar Fasciitis Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Plantar Fasciitis Treatment Market: Drug Class Business Analysis

4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
4.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
4.5. Corticosteroids
- 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
4.6. Others
- 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Plantar Fasciitis Treatment Market: Disease Type Business Analysis

5.1. Disease Type Market Share, 2024 & 2033
5.2. Disease Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
5.4. Acute Plantar Fasciitis
- 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
5.5. Chronic Plantar Fasciitis
- 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
5.6. Others
- 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Plantar Fasciitis Treatment Market: End Use Business Analysis

6.1. End Use Market Share, 2024 & 2033
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
6.4. Hospitals & Clinics
- 6.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
6.5. Ambulatory Surgical Centers
- 6.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
6.6. Others
- 6.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Plantar Fasciitis Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.4. North America
- 7.4.1. North America Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Framework
  - 7.4.2.5. U.S. Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Framework
  - 7.4.3.5. Canada Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Framework
  - 7.4.4.5. Mexico Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Europe
- 7.5.1. Europe Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Framework
  - 7.5.2.5. UK Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Framework
  - 7.5.3.5. Germany Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Reimbursement Framework
  - 7.5.4.5. France Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Target Disease Prevalence
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Reimbursement Framework
  - 7.5.5.5. Italy Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Target Disease Prevalence
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Reimbursement Framework
  - 7.5.6.5. Spain Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Target Disease Prevalence
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Reimbursement Framework
  - 7.5.7.5. Denmark Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Target Disease Prevalence
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Reimbursement Framework
  - 7.5.8.5. Sweden Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Target Disease Prevalence
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Reimbursement Framework
  - 7.5.9.5. Norway Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Framework
  - 7.6.2.5. Japan Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Framework
  - 7.6.4.5. India Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Framework
  - 7.6.5.5. Australia Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Target Disease Prevalence
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. Reimbursement Framework
  - 7.6.6.5. South Korea Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Target Disease Prevalence
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Reimbursement Framework
  - 7.6.7.5. Thailand Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7. Latin America
- 7.7.1. Latin America Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Target Disease Prevalence
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Reimbursement Framework
  - 7.7.2.5. Brazil Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Target Disease Prevalence
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Reimbursement Framework
  - 7.7.3.5. Argentina Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Target Disease Prevalence
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. Reimbursement Framework
  - 7.8.2.5. South Africa Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Target Disease Prevalence
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Reimbursement Framework
  - 7.8.3.5. Saudi Arabia Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Target Disease Prevalence
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. Reimbursement Framework
  - 7.8.4.5. UAE Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Target Disease Prevalence
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Reimbursement Framework
  - 7.8.5.5. Kuwait Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Pfizer Inc.
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Bayer AG
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Johnson & Johnson
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Viatris Inc.
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Teva Pharmaceutical Industries Ltd.
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Sanofi
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. AbbVie Inc.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. GSK plc.
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Novartis AG
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Sun Pharmaceutical Industries Ltd.
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives

한글목차

족저근막염 치료 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 족저근막염 치료 시장의 변수, 동향, 범위

제4장 족저근막염 치료 시장 : 약물 클래스별 비즈니스 분석

제5장 족저근막염 치료 시장 : 질환 유형별 비즈니스 분석

제6장 족저근막염 치료 시장 : 최종 용도별 비즈니스 분석

제7장 족저근막염 치료 시장 : 지역별 추정 및 동향 분석